{"id":"cyclophosphamide-fludarabine-thymoglobulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / neutropenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Graft-versus-host disease"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL1096882","moleculeType":"Small molecule","molecularWeight":"365.21"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cyclophosphamide is an alkylating agent that cross-links DNA and causes cell death; Fludarabine is a purine analog that inhibits DNA synthesis; Thymoglobulin (anti-thymocyte globulin) is a polyclonal antibody that depletes T cells. Together, they provide myeloablative conditioning and immunosuppression to prepare the bone marrow for transplantation and reduce graft rejection and graft-versus-host disease.","oneSentence":"This combination regimen uses chemotherapy and immunosuppression to eliminate malignant and autoreactive cells before hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:09:28.446Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for hematopoietic stem cell transplantation in pediatric hematologic malignancies"},{"name":"Preparation for allogeneic bone marrow transplantation"}]},"trialDetails":[{"nctId":"NCT06872333","phase":"PHASE2","title":"Allo HSCT for High Risk Hemoglobinopathies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-11-19","conditions":"Graft Failure, Sickle Cell Disease, Hemoglobinopathies","enrollment":62},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT04784052","phase":"PHASE1, PHASE2","title":"Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab","status":"RECRUITING","sponsor":"Porteus, Matthew, MD","startDate":"2021-12-07","conditions":"Fanconi Anemia","enrollment":18},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT07052370","phase":"PHASE1","title":"TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-09-25","conditions":"Hematologic Malignancy","enrollment":30},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT04540380","phase":"PHASE1","title":"Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-01","conditions":"Renal Failure","enrollment":20},{"nctId":"NCT02143830","phase":"PHASE2","title":"HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2014-04","conditions":"Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS)","enrollment":70},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT04872595","phase":"PHASE2","title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)","enrollment":59},{"nctId":"NCT03240731","phase":"PHASE2","title":"HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2017-08-10","conditions":"Sickle Cell Disease","enrollment":25},{"nctId":"NCT03531736","phase":"PHASE1","title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-09","conditions":"Myeloid Diseases","enrollment":17},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT02928991","phase":"EARLY_PHASE1","title":"Fludarabine Based RIC for Bone Marrow Failure Syndromes","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2015-04","conditions":"Bone Marrow Failure Syndromes","enrollment":25},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT06512545","phase":"NA","title":"Modified Second Haplo-transplantation for Graft Failure","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Graft Failure, Stem Cell Transplant Complications","enrollment":12},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT06646497","phase":"PHASE2","title":"Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-01","conditions":"Aplastic Anemia","enrollment":52},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT03079089","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2017-06-30","conditions":"Refractory or Relapsed Lymphoid Haemopathy","enrollment":40},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT05832515","phase":"PHASE1","title":"AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-10-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06199427","phase":"PHASE2","title":"PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-11-21","conditions":"Inborn Errors of Immunity","enrollment":100},{"nctId":"NCT01850108","phase":"NA","title":"Non-Myeloablative Conditioning and Bone Marrow Transplantation","status":"UNKNOWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2013-05","conditions":"Sickle Cell Disease, Hemoglobinopathies","enrollment":26},{"nctId":"NCT06198842","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2023-11-22","conditions":"Nijmegen Breakage Syndrome","enrollment":10},{"nctId":"NCT05126849","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-06","conditions":"Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":31},{"nctId":"NCT06098326","phase":"PHASE2","title":"CyFluATG in Lower Risk MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2018-03-06","conditions":"Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT02757885","phase":"PHASE2","title":"Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-07-10","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT01860170","phase":"PHASE1, PHASE2","title":"Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2012-04","conditions":"Hematological Malignancy","enrollment":28},{"nctId":"NCT02224872","phase":"PHASE2","title":"Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08","conditions":"Severe Aplastic Anemia, Bone Marrow Failure Syndromes","enrollment":18},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT03035422","phase":"NA","title":"Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2018-01-15","conditions":"Refractory Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03263767","phase":"PHASE2","title":"Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2018-01-15","conditions":"Graft Versus Host Disease","enrollment":47},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT03412266","phase":"PHASE2","title":"RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT03600909","phase":"PHASE2","title":"A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-15","conditions":"Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)","enrollment":3},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT03593902","phase":"PHASE2, PHASE3","title":"Cardiac Safe Transplants for Systemic Sclerosis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-05-17","conditions":"Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT03955601","phase":"PHASE2","title":"A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:","status":"UNKNOWN","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2018-07-12","conditions":"Aplastic Anemia Idiopathic","enrollment":30},{"nctId":"NCT01445821","phase":"PHASE3","title":"Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2011-09-15","conditions":"Scleroderma, Systemic","enrollment":44},{"nctId":"NCT04400045","phase":"PHASE2","title":"Low Dose Treosulfan Based Conditioning Regimen in HSCT for Nijmegen Breakage Syndrome","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2020-05-22","conditions":"Nijmegen Breakage Syndrome","enrollment":10},{"nctId":"NCT01370213","phase":"PHASE2","title":"NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT00566696","phase":"PHASE2","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-14","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML)","enrollment":73},{"nctId":"NCT03821987","phase":"NA","title":"Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-17","conditions":"Aplastic Anemia, Stem Cell Transplant Complications, Engraft Failure","enrollment":55},{"nctId":"NCT00498316","phase":"PHASE1","title":"Cord Blood Expansion on Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-03","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":98},{"nctId":"NCT02080195","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09-13","conditions":"Lupus Erythematosus, Graft-versus-host Disease","enrollment":1},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT02627573","phase":"PHASE2","title":"Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2015-07","conditions":"Leukemia, Chronic Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative","enrollment":32},{"nctId":"NCT01279616","phase":"PHASE2","title":"A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2010-09","conditions":"Sickle Cell Disease","enrollment":8},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT01049854","phase":"PHASE2","title":"CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2011-09","conditions":"Leukemia, Lymphoma, Bone Marrow Failure","enrollment":20},{"nctId":"NCT00278512","phase":"PHASE1","title":"Hematopoietic Stem Cell Support in Vasculitis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-08","conditions":"Vasculitis","enrollment":7},{"nctId":"NCT02428517","phase":"","title":"Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2015-04","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":20},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT00113828","phase":"PHASE2","title":"Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Lymphoma, Leukemia, Multiple Myeloma","enrollment":5},{"nctId":"NCT00303667","phase":"PHASE1, PHASE2","title":"Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-01","conditions":"Acute Myelogenous Leukemia","enrollment":50},{"nctId":"NCT00455312","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-08","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":36},{"nctId":"NCT03246178","phase":"NA","title":"Haploidentical Transplantation in Severe Aplastic Anemia","status":"UNKNOWN","sponsor":"Wu Xiaoxiong","startDate":"2017-07-10","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT01362452","phase":"PHASE1","title":"Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-07","conditions":"Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT03190733","phase":"PHASE4","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2017-08-30","conditions":"Chronic Graft-versus-host-disease, Leukemia Relapse","enrollment":192},{"nctId":"NCT01158118","phase":"PHASE2","title":"Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-04-01","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin","enrollment":48},{"nctId":"NCT03171831","phase":"PHASE4","title":"Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2017-04-01","conditions":"Thalassemia Major","enrollment":30},{"nctId":"NCT02472392","phase":"PHASE1","title":"Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-04","conditions":"EWINGS SARCOMA","enrollment":10},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":34},{"nctId":"NCT00916045","phase":"PHASE2","title":"Pilot Study of Unrelated Cord Blood Transplantation","status":"TERMINATED","sponsor":"King's College Hospital NHS Trust","startDate":"2009-09","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Lymphoblastic, Acute","enrollment":40},{"nctId":"NCT00589563","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-05","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection","enrollment":32},{"nctId":"NCT00025038","phase":"PHASE2","title":"Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Juvenile Myelomonocytic Leukemia","enrollment":100},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT01145976","phase":"PHASE3","title":"Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-03","conditions":"Aplastic Anemia","enrollment":98},{"nctId":"NCT01087398","phase":"PHASE2, PHASE3","title":"Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2009-09","conditions":"Osteopetrosis","enrollment":10},{"nctId":"NCT01238328","phase":"PHASE2, PHASE3","title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2009-09","conditions":"Mucopolysaccharidosis","enrollment":10},{"nctId":"NCT01129323","phase":"NA","title":"Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-11","conditions":"Severe Aplastic Anemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cyclophosphamide, Fludarabine, Thymoglobulin","genericName":"Cyclophosphamide, Fludarabine, Thymoglobulin","companyName":"The Korean Society of Pediatric Hematology Oncology","companyId":"the-korean-society-of-pediatric-hematology-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses chemotherapy and immunosuppression to eliminate malignant and autoreactive cells before hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in pediatric hematologic malignancies, Preparation for allogeneic bone marrow transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}